<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00587145</url>
  </required_header>
  <id_info>
    <org_study_id>NCCCTS-06-190</org_study_id>
    <secondary_id>82-31-920-1609</secondary_id>
    <nct_id>NCT00587145</nct_id>
  </id_info>
  <brief_title>Phase II Study of Perioperative S-1 Plus Docetaxel in Patients With Localized Advanced Gastric Cancer</brief_title>
  <official_title>Phase II Study of Perioperative S-1 Plus Docetaxel in Patients With Localized Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open-label, single center, and a single arm phase II study to evaluate the
      clinical response and safety of perioperative S-1 plus docetaxel. Perioperative chemotherapy
      is composed of 3 cycles of preoperative S-1/docetaxel and 3 cycles of postoperative
      S-1/docetaxel.Chemotherapy regimen:

        -  S-1 80 mg/m2/day every 12-h p.o. on days 1(evening)-15 (morning)

        -  Docetaxel 35 mg/m2 mixed in d5w 250 ml iv over 60-min on days 1 and 8
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2006</start_date>
  <completion_date type="Anticipated">May 2009</completion_date>
  <primary_completion_date type="Anticipated">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the clinical responses to preoperative S-1 plus docetaxel</measure>
    <time_frame>During chemotherapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the clinical downstaging,the pathologic responses, toxicity profile,the disease-free survival,overall survival,the effect of CYP2A6 genetic polymorphisms on the pharmacokinetics and the difference in pharmacokinetics between before and after gastrectomy</measure>
    <time_frame>During study period</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Stomach Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1,Docetaxel</intervention_name>
    <description>S-1 80 mg/m2/day every 12-h p.o. on days 1(evening)-15 (morning)
Docetaxel 35 mg/m2 mixed in d5w 250 ml iv over 60-min on days 1 and 8</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically or cytologically confirmed localized gastric adenocarcinoma as defined
             by CT stage III and IV (M0) (but not N3, which is metastatic node in WHO TNM
             classification), according to Japanese TNM classification system

          2. No distant metastatic disease in laparoscopy

          3. Age: 18-70 years

          4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          5. Disease status must be that of measurable disease as defined by RECIST: Measurable
             lesions: lesions that can be accurately measured in at least one dimension by
             abdominal CT, if the longest diameter to be recorded is at least 10 mm with spiral CT

          6. Adequate major organ function including the following: Hematopoietic function: WBC ³
             4,000/mm3, ANC ³ 1,500/mm3, Platelet ³ 100,000/mm3Hepatic function: serum bilirubin £
             1.5 mg/dl, AST/ALT levels £ 2.5 x UNLRenal function: serum creatinine £ 1.5 mg/dl

          7. Patients should sign a written informed consent before study entry

        Exclusion Criteria:

          1. CT Stage I, II, M1 or N3, which is metastatic node in WHO TNM classification,
             according to Japanese TNM classification system

          2. Prior chemotherapy or radiotherapy

          3. Inadequate cardiovascular function:New York Heart Association class III or IV heart
             diseaseUnstable angina or myocardial infarction within the past 6 monthsHistory of
             significant ventricular arrhythmia requiring medication with antiarrhythmics or
             significant conduction system abnormality

          4. Serious concurrent infection or nonmalignant illness that is uncontrolled or whose
             control may be jeopardized by complications of study therapy

          5. Other malignancy within the past 3 years except non-melanomatous skin cancer or
             carcinoma in situ of the cervix

          6. Psychiatric disorder that would preclude compliance

          7. Pregnant, nursing women or patients with reproductive potential without contraception

          8. Patients receiving a concomitant treatment with drugs interacting with S-1 such as
             flucytosine, phenytoin, or warfarin et al.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sook Ryun Park, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Center, Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sook Ryun Park, M.D</last_name>
    <phone>+82-31-920-1609</phone>
    <email>sukryun73@ncc.re.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>So Yun Park, MS</last_name>
    <phone>+82-31-920-2307</phone>
    <email>tomongmong@naver.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Cancer Center Korea</name>
      <address>
        <city>Goyang,</city>
        <state>Gyeonggi</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sook Ryun Park, M.D</last_name>
      <phone>+82-31-920-1609</phone>
      <email>sukryun73@ncc.re.kr</email>
    </contact>
    <contact_backup>
      <last_name>So Yun Park, MS</last_name>
      <phone>+82-31-920-2307</phone>
      <email>tomongmong@naver.com</email>
    </contact_backup>
    <investigator>
      <last_name>Noe Kyeong Kim, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Young Iee Park Park, M.D.Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Young Woo Kim,, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Keun Won Ryu, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jun Ho Lee, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Il Ju Choi, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chan Gyoo Kim, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jong-Yeul Lee, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jong Seok Lee, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Myeong-Cherl Kook Kook, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hyeong-Seok Lim, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2007</study_first_submitted>
  <study_first_submitted_qc>December 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2008</study_first_posted>
  <last_update_submitted>December 21, 2007</last_update_submitted>
  <last_update_submitted_qc>December 21, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2008</last_update_posted>
  <responsible_party>
    <name_title>Sook Ryun Park, M.D.</name_title>
    <organization>National Cancer Center, Korea</organization>
  </responsible_party>
  <keyword>Stomach Neoplasms</keyword>
  <keyword>Secondary</keyword>
  <keyword>Combination chemotherapy</keyword>
  <keyword>S-1</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>oxaliplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

